

3rd IBD ACADEMY

September 26th & 27th, 2025

Hotel Mellain, Tuzla

ACADEMY PROGRAM



ASOCIJACIJA
GASTROENTEROLOGA
I HEPATOLOGA
U BOSNI I HERCEGOVINI



freestyle
medical marketing

3rd IBD ACADEMY PROGRAM

FRIDAY- 26.09.2025.

09:00 – 09:20 Registration

09:20 – 09:30 Welcome Address - Bašić Denjagić Mirela (BiH)

🕒 09:30 – 11:00 Session No 1

👤 Moderators: Bevanda Milenko (BiH), Jovanović Predrag (BiH), Mesihović Rusmir (BiH)

09:30 - 09:45 How do we differentiate IBD from other diseases? What are the key clinical, endoscopic and radiologic clues?

Babić Emil (BiH)

09:45 - 10:00 How should we use and interpret fecal calprotectin in patients with unclear symptoms and in those with known IBD?

Hodžić Selma (BiH)

10:00 - 10:15 When is the right time for follow-up endoscopy, should we take biopsies, and what are the challenges in endoscopic scoring?

Bišćanin Alen (Croatia)

10:15 - 10:30 When should we use intestinal ultrasound for diagnosis, and when for disease monitoring?

Kralj Dominik (Croatia)

10:30 - 10:45 What is the role of histopathology in the diagnosis and long-term monitoring of IBD?

Poljašević Rahmanović Nevena (BiH)

10:45 - 11:00 Discussion

11:00 - 11:15 Industry-sponsored satellite symposium – Pontus Pharma

11:15 - 11:30 Industry-sponsored satellite symposium – Hemofarm

☕ 11:30 - 11:50 Coffee Break

🕒 11:50– 13:20 Session No 2

👤 Moderators: Kalaba Ana (Serbia), Bišćanin Alen (Croatia), Babić Emil (BiH)

11:50 - 12:05 How should we evaluate and treat mild Crohn's disease?
Husić Azra (BiH)

12:05 - 12:20 How should we manage mild to moderate ulcerative colitis, and what is the optimal use of 5-ASA in IBD?

Tomašić Vedran (Croatia)

12:20-12:35 What are the most common functional gastrointestinal disorders in IBD patients, and how should we treat them?

Jovanović Predrag (BiH)

12:35– 12:50 How do we diagnose, treat and monitor Crohn's disease of the mid and proximal small bowel?

Sokić Milutinović Aleksandra (Serbia)

12:50 - 13:05 What is the first-line approach to diagnosing and treating perianal Crohn's disease?

Smolović Brigita (Montenegro)

13:05 - 13:20 - Discussion

13:20 – 13:35 Industry-sponsored satellite symposium – Oktal Pharma

13:35– 13:50 Industry-sponsored satellite symposium – Hercegovinalijek (Abbvie)

13:50 – 15:00 🍴 Lunch

🕒 15:00 – 16:15 Session No 3

👤 Moderators: Vanis Nenad (BiH), Alibegović Ervin (BiH), Troškot Perić Rosana (Croatia)

15:00 - 15:15 What preparations are necessary before starting biologic therapy, and why do they matter?

Zubčević Nadža (BiH)

15:15 - 15:30 What are the risks of advanced therapies in IBD, and how do we effectively communicate them to patients without causing unnecessary fear?

Tamburić Renata (BiH)

15:30 - 15:45 Can biologics be reintroduced after a prolonged drug holiday or reused after primary loss of response?

Drobne David (Slovenia)

15:45 - 16:00 How can we manage steroid dependence in IBD, and what strategies help us minimize steroid exposure?

Karin Maja (BiH)

16:00 - 16:15 Discussion

 **16:15 - 16:30** Coffee Break


 **16:30 - 17:30 Panel Discussion 1**

Moderators: Bašić Denjagić Mirela (BiH), Jovanović Predrag (BiH).

Case Presentation: Dizdarević Naid (BiH), Selimović Nedim (BiH), Odobašić Faris (BiH)

Panel Topics:


- How do we approach latent or active tuberculosis in IBD patients?
- How should Clostridium difficile infection be managed in patients with IBD?
- What is the optimal approach to thromboembolism risk and treatment in IBD?

 Panelists: Bošnjčić Jasmina (BiH), Porobić Jahić Humera (BiH), Tihić Nijaz (BiH) Rakovac-Tupković Lejla (BiH)

 **20:00 Dinner - Restaurant Don Papa (Address: Trg Slobode, Tuzla)**

SATURDAY 27.09.2025

 **09:30 - 10:45 Session No 4**

 Moderators: Tarabar Dino (Serbia), Tomašić Vedran (Croatia), Pilav Aida (BiH)

09:30 - 09:45 What is the role of probiotics, prebiotics and dietary supplements in IBD management?

Mehmedović Majda (BiH)

09:45 - 10:00 Can cannabis help our patients with IBD? What should we tell them when they ask about it?

Milenković Zoran (Serbia)

10:00 - 10:15 What are the potential benefits of hyperbaric oxygen therapy in refractory IBD patients?

Barać Tatjana (BiH).

10:15 - 10:30 What does disease modification in IBD mean, and how can we "stop the clock"?

Tarabar Dino (Serbia)

10:30 - 10:45 How and when should proactive therapeutic drug monitoring be applied in IBD? What are the optimal cut-off values in various clinical scenarios?

Marković Srđan (Serbia)

10:45 - 10:55 Discussion

10:55 - 11:25 Industry sponsored satellite symposium Takeda

 **11:25 - 11:45** Coffee Break


 **11:45 - 12:30 Panel Discussion 2**

 Moderators: Bašić Denjagić Mirela (BiH), Jovanović Predrag (BiH)

 Case Presentations - Kralj Đorđe (Serbia), Sakić Azra (BiH), Huremović Amila (BiH)

Panel Topics:

- How should we approach the risk of malignancy in IBD?
- What is the relationship between IBD and liver cancer?
- How should we manage skin cancers (malignant melanoma and non-malignant) in IBD patients?
- How should we approach colorectal cancer in IBD patients?


 Panelists: Memedović Majda (BiH), Mehmedović Zlatan (BiH), Alidžanović Nurkanović Lejla (BiH), Rakovac Tupković Lejla (BiH)

 **12:30 - 13:15 Panel Discussion 3**

 Moderators: Bašić Denjagić Mirela (BiH), Jovanović Predrag (BiH)

Panel Topics:

- How should we screen IBD patients for depression and anxiety?
- Do IBD patients have the right to disability status, and how is it evaluated?
- What are the challenges in managing anxiety, depression, school absenteeism, and diet in the pediatric IBD population?
- What are the most commonly used supplements among IBD patients?

 Panelists: Softić Rusmir (BiH), Pranjic Nurka (BiH), Selimović Amela (BiH), Šabanović Marizela (BiH).

13:15 – 13:45 Panel Discussion 4

 Moderators: Bašić Denjagić Mirela (BiH), Jovanović Predrag (BiH)

 Case Presentations – Pjanić Mirha (BiH), Klapić Alma (BiH), Kešetović Ilma (BiH)

Panel Theme:

- Blame it on IBD – or at least consider it!"
- When does nephrolithiasis become a complication or the first indicator of IBD?"
- When is 5-ASA not the primary culprit in renal failure among IBD patients?
- When is an iliopsoas abscess best managed by a specialist other than an orthopedic surgeon?


 Panelists: Škoberne Andrej (Slovenia), Alečković Halilović Mirna (BiH), Mehmedović Zlatan (BiH)

13:45 Conclusion and Farewell Remarks

14:00 – 15:00  Lunch

SATURDAY 27.09.2025

Parallel Program for Nurses

 Moderators: Mičić Šejla (BiH), Čarković Selim (BiH), Rakičević Svetlana (Serbia)

09:30 – 11:25

09:30 – 09:45 What are the most common everyday challenges nurses face in the care of IBD patients?

Rakičević Svetlana (Serbia)

09:45 – 10:00 What does It mean to Live with IBD from a nursing perspective?

Sošić Tanja (Montenegro)

10:00 – 10:15 What causes fatigue in IBD patients, and how can we help them manage it?

Jelisavac Daliborka (BiH)

10:15 – 10:30 What is the role of the nurse in supporting both patients and their families?

Cviko Medina (BiH)

10:30 – 10:45 How should biologic therapy be used in patients with a history of malignancy?

Isaković Firdevsa (BiH)

10:45 – 11:00 What is the experience of IBD nurses with biologics and advanced therapies?

Bošnjak Martina (BiH)

11:00 – 11:25 Discussion

 **11:25 – 11:45** Coffee Break

Gold sponsor:


PONTUS

 OKTAL PHARMA

 Hemofarm
STADA GRUPA

Main sponsor:



Academy partners:

 BOSNALIJEK
Prvo zdravlje!

 MEDIS


NOBEL


SALVEO
BIRAM ZDRAVLJE

Silver sponsor:

 ewo pharma 
since 1959



HERCEGOVINALIJEK


SALVEO
BIRAM ZDRAVLJE



SANDOZ

 PRO.MED.CS
Praha a.s.

 Amicus
a Swixx BioPharma company